Vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
Vitamin D given to infants may leads to lower vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L compared with placebo or no treatment (low certainty).
1 finding from 1 review
Vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
It is very uncertain whether vitamin D given to infants changes vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serum 25‐OH vitamin D level at latest time reported nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
1 finding from 1 review
Serum 25‐OH vitamin D level at latest time reported nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
1 finding from 1 review
Vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
Vitamin D given to lactating mothers may leads to lower vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L compared with placebo or no treatment (low certainty).
1 finding from 1 review
Vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
Vitamin D given to lactating mothers may leads to lower vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L compared with placebo or no treatment (low certainty).
1 finding from 1 review
Maternal vitamin B12 deficiency · pregnant women
It is very uncertain whether summary of findings table ‐ Vitamin B12 supplementation changes maternal vitamin B12 deficiency compared with placebo/no vitamin B12 supplementation (very low certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
It is very uncertain whether vitamin K antagonists changes symptomatic PE compared with placebo or no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic DVT compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with active control (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with active control (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic PE compared with active control (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic DVT compared with active control (moderate certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found